Concepedia

Author

Richard Dillon

King's College LondonORCID

Also Known As

Dillon, Dillon, Richard, Katherine Bailey, R Dillon, R. Dillon, Richard Dillon, Richard James Dillon, Rosalie Dillon

202

Publications

4K

Citations

31

H-Index

61

Concepts

All Affiliations

King's College LondonGuy's and St Thomas' NHS Foundation TrustCardiff UniversityUniversity of BirminghamUniversity College London
RD

About

Richard Dillon is an author at King's College London specializing in medicine, hematology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

1.7K

2

Health Sciences

9

9

1.2K

3

Cell Biology

4

4

135

4

Blood Transplantation

1

1

15

5

Cellular Therapies

1

1

37

Richard Dillon

×

54

Publications

3.4K

Citations

28

H-Index

YearCitations

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele,

Blood

2021

666

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

Sheng Li, Francine E. Garrett-Bakelman, Stephen S. Chung,

Nature Medicine

2016

393

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations

Sylvie Freeman, Robert K. Hills, Paul Virgo,

Journal of Clinical Oncology

2018

195

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

Richard Dillon, Robert K. Hills, Sylvie Freeman,

Blood

2020

160

Unified classification and risk-stratification in Acute Myeloid Leukemia

Yanis Tazi, Juan E. Arango‐Ossa, Yangyu Zhou,

Nature Communications

2022

159

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

Charles Craddock, Aimee Jackson, Justin Loke,

Journal of Clinical Oncology

2020

158

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Faisal Basheer, George Giotopoulos, Eshwar Meduri,

The Journal of Experimental Medicine

2019

118

Venetoclax induces rapid elimination of <i>NPM1</i> mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Ing Soo Tiong, Richard Dillon, Adam Ivey,

British Journal of Haematology

2020

86

Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis

Aileen Rowan, Richard Dillon, Aviva Witkover,

Blood

2020

78

Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Sun Loo, Richard Dillon, Adam Ivey,

Blood

2022

75

Page 1